Cuprina Holdings (Cayman) Limited is trading 31.6% down at $5.75 as the stock pulls back following an extreme multi-day rally triggered by U.S. FDA 510(k) clearance for its MEDIFLY Maggots wound-care product.

  • The stock had previously surged 112% to reach $8.41 on June 15, 2026, in response to the regulatory milestone.
  • Current price action reflects short-term traders locking in gains and the share price normalizing after the recent spike.